Bio Green Med Solution Reports Q3 Financial Results

Bio Green Med Solution ( (BGMS) ) has issued an announcement.

On November 13, 2025, Bio Green Med Solution reported its third-quarter financial results, highlighting several strategic moves to strengthen its market position. Key developments included a reverse stock split in July, a warrant exchange agreement in September, and the acquisition of Fitters Sdn. Bhd., which became a wholly-owned subsidiary. The company also sold assets related to Plogosertib, a cancer treatment, and declared a cash dividend on its preferred stock. Financially, the company reported a net loss of $1.0 million for the quarter, with cash reserves expected to support operations into early 2026.

Spark’s Take on BGMS Stock

According to Spark, TipRanks’ AI Analyst, BGMS is a Underperform.

Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.

To see Spark’s full report on BGMS stock, click here.

More about Bio Green Med Solution

Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) is a diversified company that has transitioned from the biopharmaceutical industry to focus on fire safety protection and distribution activities. Headquartered in Malaysia, the company completed the acquisition of Fitters Sdn. Bhd., a specialist in fire protection products and services, in September 2025.

Average Trading Volume: 500,940

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.22M

Find detailed analytics on BGMS stock on TipRanks’ Stock Analysis page.